|drug720||Cell therapy protocol 1 Wiki||1.00|
|D012127||Respiratory Distress Syndrome, Newborn NIH||0.08|
|D055371||Acute Lung Injury NIH||0.08|
|D012128||Respiratory Distress Syndrome, Adult NIH||0.07|
There is one clinical trial.
Acute Respiratory Distress Syndrome (ARDS) is the major cause of death in the COVID-19 pandemic. In this trial, the safety and efficacy of Mesenchymal Stem Cells (MSC) for the treatment of ARDS in COVID-19 patients will be assessed.
Description: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0Measure: Adverse events assessment Time: From baseline to day 28
Description: Evaluation of Pneumonia ImprovementMeasure: Blood oxygen saturation Time: From baseline to day 14
Description: Number of daysMeasure: Intensive care unit-free days Time: Up to day 8
Description: Improvement of clinical symptoms including duration of fever, respiratory distress, pneumonia, cough, sneezingMeasure: Clinical symptoms Time: From baseline to day 14
Description: increase in PaO2/FiO2 ratio from baseline to day 7Measure: Respiratory efficacy Time: From baseline to day 7
Description: Biochemical examinationMeasure: Biomarkers concentrations in plasma Time: At baseline, 7, 14, 28 days after the first intervention
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports